Chronic Nonmalignant Pain in Primary Care



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2008 Nov 15;78(10):1155-1162.

  Patient information: See related handout on chronic pain, written by the authors of this article.

  Related Editorial

The online version of this article includes suppemental content.

A systematic approach to chronic nonmalignant pain includes a comprehensive evaluation; a treatment plan determined by the diagnosis and mechanisms underlying the pain; patient education; and realistic goal setting. The main goal of treatment is to improve quality of life while decreasing pain. An initial comprehensive pain assessment is essential in developing a treatment plan that addresses the physical, social, functional, and psychological needs of the patient. One obstacle to appropriate pain management is managing the adverse effects of medication. Opioids pose challenges with abuse, addiction, diversion, lack of knowledge, concerns about adverse effects, and fears of regulatory scrutiny. These challenges may be overcome by adherence to the Federation of State Medical Boards guidelines, use of random urine drug screening, monitoring for aberrant behaviors, and anticipating adverse effects. When psychiatric comorbidities are present, risk of substance abuse is high and pain management may require specialized treatment or consultation. Referral to a pain management specialist can be helpful.

Pain is an unpleasant sensory and emotional experience primarily associated with tissue damage or described in terms of such damage. More than 50 million Americans have chronic pain.1 Chronic nonmalignant pain is pain unrelated to cancer that persists beyond the usual course of disease or injury. It may or may not be associated with a pathologic process.1,2 The estimated annual costs related to chronic pain are $85 to $90 billion.3

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Assessing for risk of abuse should be an integral part of chronic pain management.

C

5, 6, 28

A written plan for treating chronic pain should state objectives to determine success, state if further diagnostic tests are indicated, address psychosocial and physical function, adjust therapy to meet the needs of the patient, and use nondrug treatment modalities in addition to medication.

C

2

Patients taking long-acting opioids for chronic nonmalignant pain should be started on long-term preventive therapy with a combination stimulant/softener laxative for constipation.

B

37


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Assessing for risk of abuse should be an integral part of chronic pain management.

C

5, 6, 28

A written plan for treating chronic pain should state objectives to determine success, state if further diagnostic tests are indicated, address psychosocial and physical function, adjust therapy to meet the needs of the patient, and use nondrug treatment modalities in addition to medication.

C

2

Patients taking long-acting opioids for chronic nonmalignant pain should be started on long-term preventive therapy with a combination stimulant/softener laxative for constipation.

B

37


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Evaluation

Evaluating patients with chronic non-malignant pain requires a systematic approach that encompasses the pathophysiologic, as well as the social and psychological aspects of the condition.2,4 Identifying the pain as nociceptive (tissue injury), neuropathic (a neurologic response to neural or nonneural injury), or mixed; and, if possible, quantifying the pain using visual analog scales will aid in treatment decisions. A thorough social and psychiatric history may alert the physician to issues, such as current or past substance abuse, developmental history, depression, anxiety, or other factors, that may interfere with achieving treatment goals. Validated risk assessment tools for persons at higher risk of opioid abuse include the Opioid Risk Tool (http://www.emergingsolutionsinpain.com/index.php?option=com_content&task=view&id=101&Itemid=100) and the Screener and Opioid Assessment for Patients with Pain–Revised (http://www.painedu.com/soap.asp).5,6 These tools should not be used to deny a patient pain medication, but to help develop a plan for medication monitoring. Pain contracts and visual analog scales can be found at http://www.ohsu.edu/ahec/pain/form.html.5-7  By identifying patients at risk of possible opioid misuse (e.g., persons with past or current substance abuse, persons with psychiatric issues), physicians can choose to modify the monitoring plan or to refer the patient to a pain specialist. Table 1 provides definitions for the terminology used to describe medication dependence and abuse.2

Table 1

Terminology for Medication Dependence and Abuse

Term Definition

Addiction

Neurobiologic, multifactorial disease characterized by impaired control, compulsive drug use, and continued use despite harm

Physical dependence

Normal adaptive state that results in withdrawal symptoms if the drug is abruptly stopped or decreased

Pseudoaddiction

Relief-seeking behaviors misinterpreted as drug-seeking behaviors that resolve upon institution of effective analgesic therapy

Substance abuse

Use of any substance for purposes that are non-therapeutic or are not those for which it is prescribed

Tolerance

Physiologic state from regular drug use in which an increased dosage is needed to produce the same effect


Information from reference 2.

Table 1   Terminology for Medication Dependence and Abuse

View Table

Table 1

Terminology for Medication Dependence and Abuse

Term Definition

Addiction

Neurobiologic, multifactorial disease characterized by impaired control, compulsive drug use, and continued use despite harm

Physical dependence

Normal adaptive state that results in withdrawal symptoms if the drug is abruptly stopped or decreased

Pseudoaddiction

Relief-seeking behaviors misinterpreted as drug-seeking behaviors that resolve upon institution of effective analgesic therapy

Substance abuse

Use of any substance for purposes that are non-therapeutic or are not those for which it is prescribed

Tolerance

Physiologic state from regular drug use in which an increased dosage is needed to produce the same effect


Information from reference 2.

Nonverbal patients require modified assessment techniques. Nonverbal patients may communicate pain by moaning, screaming, crying, or making painful facial expressions during manipulation. They may have swelling, may not use the (affected) body part, or may not move the body in a specific way.8 Verbal and nonverbal patients with cognitive or intellectual disabilities can have sensory integration or more global communication disorders; therefore, they may not exhibit this type of non-verbal communication. Instead, chronic nonmalignant pain could present as behavioral challenges or as a gradual decline in function. Appropriate treatment can greatly improve patient quality of life and caregiver stress.

When long-term opioid therapy is considered in a patient with chronic nonmalignant pain, the initial pain assessment note should provide a complete and focused summary of the circumstances leading to the decision to treat with long-term opioids. To provide baseline information for future assessment, the note should cover the diagnosis, quality of the pain (e.g., what palliates and provokes it, radiation, severity, type, temporal sequence), region of the pain, treatments (current and previous), referrals, studies ordered, patient risk factors, and any psychiatric or social considerations.2,4,9

Management of Chronic Nonmalignant Pain

TREATMENT PLAN

Figure 1 5-7,9 describes a general approach to assessing chronic nonmalignant pain. Management guidelines for specific pain disorders, such as chronic musculoskeletal pain, neuropathic pain, fibromyalgia, and low back pain, have been developed; therefore, a specific diagnosis should be pursued when possible.10-13 Treatment goals focus on the improvement of the social, occupational, psychological, interpersonal, and physical disabilities caused by chronic pain, which adversely affect the patient's quality of life.14 Patient education and setting realistic goals are keys to successful management; these will vary from patient to patient.15 For example, total elimination of pain is rarely a realistic goal, whereas goals to increase pleasurable activities may be achievable.

Assessment of Chronic Nonmalignant Pain

Figure 1.

Algorithm for a general approach to the assessment of chronic nonmalignant pain. (ORT = Opioid Risk Tool; SOAPP-R = Screener and Opioid Assessment for Patients with Pain–Revised.)

Information from references 5 through 7, and 9.

View Large

Assessment of Chronic Nonmalignant Pain


Figure 1.

Algorithm for a general approach to the assessment of chronic nonmalignant pain. (ORT = Opioid Risk Tool; SOAPP-R = Screener and Opioid Assessment for Patients with Pain–Revised.)

Information from references 5 through 7, and 9.

Assessment of Chronic Nonmalignant Pain


Figure 1.

Algorithm for a general approach to the assessment of chronic nonmalignant pain. (ORT = Opioid Risk Tool; SOAPP-R = Screener and Opioid Assessment for Patients with Pain–Revised.)

Information from references 5 through 7, and 9.

TREATMENT OPTIONS

Evidence of the effectiveness of most treatment options is lacking or inconsistent. Treatment options are listed in Table 2.16-25 Most chronic pain disorders respond best to a combination of treatment modalities or a multidisciplinary plan. Treatment with nonpharmacologic options, with or without the addition of medication, should be tried initially. Nonpharmacologic modalities require patient participation and motivation, and improve physical mobility, fitness, mood, sleep, and general health.26,27 Treatment of comorbid conditions, depression, anxiety, and sleep issues that commonly accompany chronic pain disorders can improve overall function.26,27 Pharmacologic choices depend upon the diagnosis and whether the mechanism of pain is characterized as neuropathic, nociceptive, or mixed. Neuropathic pain disorders involve abnormal nerve conduction and neuropathies, whereas nociceptive pain includes muscular, inflammatory, or mechanical compression disorders.9 Online Figure A describes the management of chronic nonmalignant pain by mechanism.

Table 2

Treatment Options for Chronic Nonmalignant Pain

Treatment type Options

Nonpharmacologic

Lifestyle

Cessation of tobacco products, weight loss

Physical

Exercise*, manipulation, physical therapy, stretching and yoga, surgical therapies (nerve blocks, trigger point injections, spinal infusion or stimulation), transcutaneous electric nerve stimulation

Psychologic

Biofeedback, cognitive behavior therapy†, counseling, hypnosis, music‡, relaxation†

Complementary or alternative

Acupuncture, herbal remedies, massage, mindfulness meditation, reflexology

Occupational

Occupational therapy, work conditioning programs

Pharmacologic

Nonopioid analgesics

Acetaminophen, NSAIDs, salicylates (aspirin)

Opioid medications (nonsynthetic, synthetic)§‖

Combination opioid and nonopioid medications (codeine, hydrocodone [Hycodan], or oxycodone [Roxicodone] plus acetaminophen, aspirin, or an NSAID)

Noncombination or “strong” opioid medications, such as morphine (MS Contin) and its derivatives (butorphanol [Stadol], codeine, fentanyl [Duragesic], hydrocodone, hydromorphone [Dilaudid]¶, levorphanol [Levo-Dromoran], methadone, oxycodone)

Tramadol (Ultram)

Adjuvant medications

Anticonvulsant medications (carbamazepine [Tegretol]**, gabapentin [Neurontin]**, lamotrigine [Lamictal], phenytoin [Dilantin], pregabalin [Lyrica], valproic acid [Depakene])

Antidepressants (selective serotonin reuptake inhibitors, tricyclic††)

Atypical antidepressants (duloxetine [Cymbalta], venlafaxine [Effexor]††)

Topical lidocaine (Xylocaine)‡‡

Others (topical capsaicin, cyclobenzaprine [Flexeril], lidocaine patches)


NSAID = nonsteroidal anti-inflammatory drug.

*— Aerobic exercise training has beneficial effects on physical capacity and fibromyalgia symptoms.16

†— Effective in reducing severity and frequency of chronic headaches in children and adolescents.17,18

‡— Listening to music reduces pain intensity levels and opioid requirements (magnitude of benefit is small).19

§— Intermediate-term studies showed significant effectiveness of opioids over placebo for neuropathic pain.20

‖— Chronic pain is responsive to opioid use; observational and randomized trials.21

¶— Potent analgesic that produces a dose-related response; morphine and hydromorphone have equivalent effectiveness.22

**— Effective for relieving chronic neuropathic pain.23

††— Effective for relieving neuropathic pain (effect independent of effect on depression).24

‡‡— Effective for relieving neuropathic pain.25

Information from references 16 through 25.

Table 2   Treatment Options for Chronic Nonmalignant Pain

View Table

Table 2

Treatment Options for Chronic Nonmalignant Pain

Treatment type Options

Nonpharmacologic

Lifestyle

Cessation of tobacco products, weight loss

Physical

Exercise*, manipulation, physical therapy, stretching and yoga, surgical therapies (nerve blocks, trigger point injections, spinal infusion or stimulation), transcutaneous electric nerve stimulation

Psychologic

Biofeedback, cognitive behavior therapy†, counseling, hypnosis, music‡, relaxation†

Complementary or alternative

Acupuncture, herbal remedies, massage, mindfulness meditation, reflexology

Occupational

Occupational therapy, work conditioning programs

Pharmacologic

Nonopioid analgesics

Acetaminophen, NSAIDs, salicylates (aspirin)

Opioid medications (nonsynthetic, synthetic)§‖

Combination opioid and nonopioid medications (codeine, hydrocodone [Hycodan], or oxycodone [Roxicodone] plus acetaminophen, aspirin, or an NSAID)

Noncombination or “strong” opioid medications, such as morphine (MS Contin) and its derivatives (butorphanol [Stadol], codeine, fentanyl [Duragesic], hydrocodone, hydromorphone [Dilaudid]¶, levorphanol [Levo-Dromoran], methadone, oxycodone)

Tramadol (Ultram)

Adjuvant medications

Anticonvulsant medications (carbamazepine [Tegretol]**, gabapentin [Neurontin]**, lamotrigine [Lamictal], phenytoin [Dilantin], pregabalin [Lyrica], valproic acid [Depakene])

Antidepressants (selective serotonin reuptake inhibitors, tricyclic††)

Atypical antidepressants (duloxetine [Cymbalta], venlafaxine [Effexor]††)

Topical lidocaine (Xylocaine)‡‡

Others (topical capsaicin, cyclobenzaprine [Flexeril], lidocaine patches)


NSAID = nonsteroidal anti-inflammatory drug.

*— Aerobic exercise training has beneficial effects on physical capacity and fibromyalgia symptoms.16

†— Effective in reducing severity and frequency of chronic headaches in children and adolescents.17,18

‡— Listening to music reduces pain intensity levels and opioid requirements (magnitude of benefit is small).19

§— Intermediate-term studies showed significant effectiveness of opioids over placebo for neuropathic pain.20

‖— Chronic pain is responsive to opioid use; observational and randomized trials.21

¶— Potent analgesic that produces a dose-related response; morphine and hydromorphone have equivalent effectiveness.22

**— Effective for relieving chronic neuropathic pain.23

††— Effective for relieving neuropathic pain (effect independent of effect on depression).24

‡‡— Effective for relieving neuropathic pain.25

Information from references 16 through 25.

The well-accepted concept of rational polypharmacy, where medications with variable mechanisms are combined, enhances medication effectiveness, reduces required doses, increases quality of life, and addresses sleep and mood.10,28 An example of this is the use of the tricyclic antidepressant amitriptyline for its analgesic and sedating properties (to help with insomnia). Nonopioid medications, such as acetaminophen, nonsteroidal anti-inflammatory drugs, and salicylates, should be tried initially. If ineffective, opioid/nonopioid combinations may be required, but are limited by the maximal dose of the nonopioid component. If moderate or severe pain is present, the use of long-acting opioids may be indicated, and has been shown to improve pain.20-22

OPIOID MEDICATIONS

Reluctance to use long-term opioids is generally because of concerns about abuse, addiction, diversion, and adverse effects; inadequate knowledge; and fear of regulatory scrutiny.2,29 With the increased appropriate use of opioid medications for chronic nonmalignant pain in the United States, there has been an increase in the abuse or nonmedicinal use of opioids.30 This increase is small compared with the benefits of appropriate pain management and the use of other illicit substances (e.g., cocaine, marijuana, heroin).30 There are many resources that provide detailed discussions regarding the safe, effective, and appropriate use of long-term opioids.11,15,21,31

The Federation of State Medical Boards provides guidelines for evaluating pain treatment, including appropriate chronic opioid medication use (Table 3).2 When followed carefully, these guidelines may help alleviate physician concerns. The decision to use long-term opioids requires careful consideration and is not without risk. The ineffectiveness of nonopioid options should be clearly documented, and there must be a legitimate medical purpose for opioid use. The anticipated benefits must outweigh the risks. Risk assessment tools can be used to identify patients that may be at risk of misuse. Opioid agreements are commonly used, with the intent to deter misuse and to outline patient responsibilities for obtaining opioids.31 Using an opioid agreement also provides an opportunity for a documented discussion about medication adverse effects, complications, and risks.

Table 3

Federation of State Medical Boards Criteria for Evaluating Pain Treatment, Including the Use of Controlled Substances

Step Description

Evaluation

Perform and document a medical history and physical examination that includes:

Nature and intensity of pain

Current and past treatment for pain

Underlying and coexisting disease or conditions

Effect of pain on function (physical and psychiatric)

History of substance abuse

Documentation if a controlled substance is indicated medically

Treatment

A written treatment plan should:

State objectives to determine success

State if further diagnostic tests are indicated

Address psychosocial and physical function

Adjust therapy to meet needs of patient

Informed consent and agreement for treatment

Discuss risks and benefits of drug therapy with patient or surrogate

Patient should receive prescriptions from one physician and pharmacy whenever possible

High-risk patients should have a written agreement that includes:

Urine drug screens when requested

Written documentation of refill numbers and frequency

Reasons for which drug therapy may be discontinued (violations of agreement)

Consultation

Be willing to refer; special attention should be given to patients at risk of medication misuse, abuse, or diversion

Consultation may be required in patients with psychiatric disorders or substance abuse issues (past or present)

Periodic review

Periodically review the course of pain treatment and any new information about the etiology of the pain

Evaluate and modify drug treatment based upon patient response and objective evidence of improved or diminished function; if progress is unsatisfactory, assess the appropriateness of continuing or modifying therapy

Medical records

Medical records should include:

Medical history and physical examination

Diagnostic tests and laboratory results

Evaluations and consultations

Treatment objectives and treatments

Informed consent and discussion of risks and benefits

Medication and refill documentation

Instructions and agreements

Periodic reviews

Records are to be current and easily accessible for review

Compliance with controlled substances laws and regulations

State and federal regulations must be met

Refer to U.S. Drug Enforcement Administration and state medical boards for relevant documents


Information from reference 2

Table 3   Federation of State Medical Boards Criteria for Evaluating Pain Treatment, Including the Use of Controlled Substances

View Table

Table 3

Federation of State Medical Boards Criteria for Evaluating Pain Treatment, Including the Use of Controlled Substances

Step Description

Evaluation

Perform and document a medical history and physical examination that includes:

Nature and intensity of pain

Current and past treatment for pain

Underlying and coexisting disease or conditions

Effect of pain on function (physical and psychiatric)

History of substance abuse

Documentation if a controlled substance is indicated medically

Treatment

A written treatment plan should:

State objectives to determine success

State if further diagnostic tests are indicated

Address psychosocial and physical function

Adjust therapy to meet needs of patient

Informed consent and agreement for treatment

Discuss risks and benefits of drug therapy with patient or surrogate

Patient should receive prescriptions from one physician and pharmacy whenever possible

High-risk patients should have a written agreement that includes:

Urine drug screens when requested

Written documentation of refill numbers and frequency

Reasons for which drug therapy may be discontinued (violations of agreement)

Consultation

Be willing to refer; special attention should be given to patients at risk of medication misuse, abuse, or diversion

Consultation may be required in patients with psychiatric disorders or substance abuse issues (past or present)

Periodic review

Periodically review the course of pain treatment and any new information about the etiology of the pain

Evaluate and modify drug treatment based upon patient response and objective evidence of improved or diminished function; if progress is unsatisfactory, assess the appropriateness of continuing or modifying therapy

Medical records

Medical records should include:

Medical history and physical examination

Diagnostic tests and laboratory results

Evaluations and consultations

Treatment objectives and treatments

Informed consent and discussion of risks and benefits

Medication and refill documentation

Instructions and agreements

Periodic reviews

Records are to be current and easily accessible for review

Compliance with controlled substances laws and regulations

State and federal regulations must be met

Refer to U.S. Drug Enforcement Administration and state medical boards for relevant documents


Information from reference 2

The initial medication choice depends on the pain condition, severity, comorbid disorders, and physician preference. Initial treatment requires upward dose titration to optimal effect with minimal adverse effects. Long-acting opioids are preferred because they provide consistent pain control levels. Although many authors discourage the use of short-acting opioids for chronic nonmalignant pain, breakthrough pain and acute exacerbations of pain can be addressed with short-acting opioids. Table 4 provides the six A's for monitoring patients with chronic nonmalignant pain who are taking controlled substances.11

Table 4

Six A's for Monitoring Patients with Chronic Nonmalignant Pain Taking Controlled Substances

Analgesia (assess pain relief)

Affect (evaluate mood)

Activities (evaluate activities of daily living, function, and quality of life)

Adjuncts (nonpharmacologic or nonopioid treatments)

Adverse effects (side effects of treatments)

Aberrant behavior (tolerance, dependence, and addiction)


Information from reference 11.

Table 4   Six A's for Monitoring Patients with Chronic Nonmalignant Pain Taking Controlled Substances

View Table

Table 4

Six A's for Monitoring Patients with Chronic Nonmalignant Pain Taking Controlled Substances

Analgesia (assess pain relief)

Affect (evaluate mood)

Activities (evaluate activities of daily living, function, and quality of life)

Adjuncts (nonpharmacologic or nonopioid treatments)

Adverse effects (side effects of treatments)

Aberrant behavior (tolerance, dependence, and addiction)


Information from reference 11.

PERIODIC REVIEW

Periodic review (follow-up visits) allows for the monitoring of treatment effectiveness, nonpharmacologic therapy compliance, and patient behaviors that may indicate violation of the opioid agreement or medication misuse. Periodic review also provides direction for further treatment and goal revision. Figure 2 is a sample of a tool that may be used for periodic review.11  Accurate documentation and adherence to state and federal drug regulations are essential for appropriate management (Table 3).2

Follow-up Office Visit for Chronic Nonmalignant Pain

Figure 2.

Sample monitoring template that can be used during follow-up visits for chronic nonmalignant pain. (BP = blood pressure; HEENT = head, ears, eyes, nose, throat; HR = heart rate; ROS = review of systems; RR = respiration rate).

Unvalidated form developed by Robert Jackman, MD, using information from reference 11.

View Large

Follow-up Office Visit for Chronic Nonmalignant Pain


Figure 2.

Sample monitoring template that can be used during follow-up visits for chronic nonmalignant pain. (BP = blood pressure; HEENT = head, ears, eyes, nose, throat; HR = heart rate; ROS = review of systems; RR = respiration rate).

Unvalidated form developed by Robert Jackman, MD, using information from reference 11.

Follow-up Office Visit for Chronic Nonmalignant Pain


Figure 2.

Sample monitoring template that can be used during follow-up visits for chronic nonmalignant pain. (BP = blood pressure; HEENT = head, ears, eyes, nose, throat; HR = heart rate; ROS = review of systems; RR = respiration rate).

Unvalidated form developed by Robert Jackman, MD, using information from reference 11.

DIVERSION AND ABUSE

For patients at high risk of diversion and abuse, consider the routine use of random urine drug screens to assess for presence of prescribed medications and the absence of illicit substances. Prescriptions should be appropriately written to decrease the incidence of medication misuse (e.g., write out pill count, limit to one pharmacy).32

URINE DRUG SCREENS

Urine drug screening is not legally required, but it is recommended in many guidelines.2,11 When used appropriately, urine drug screening can assist in the management of opioid therapy by uncovering illicit drug use and confirming compliance with treatment, even in the absence of behaviors suggestive of medication misuse. The urine drug screen can help solidify physician-patient trust by establishing the presence of the prescribed controlled substance in urine, thus alleviating any concerns about diversion or trafficking. Screening should be performed randomly.

Morphine can be detected in the urine for 1.0 to 1.5 days.32 Testing for synthetic controlled substances (opioids) must be done separately because standard urine drug screens only test for opiates (e.g., heroin, codeine, morphine [MS Contin]), tetra-hydrocannabinol, cocaine, phencyclidine, barbiturates, and amphetamines/methamphetamines. When interpreting urine drug screens, knowledge of metabolites and breakdown products is essential in order to avoid false-positive results (taking an unprescribed drug). For example, codeine is broken down to smaller amounts of morphine, thus the screen will be positive for both if the patient takes codeine. Hydrocodone (Hycodan) is metabolized to hydromorphone (Dilaudid). Codeine, if taken in high quantities, can also be metabolized to small amounts of hydrocodone.32 Before urine drug screening, physicians should explain their policy for a positive result to the patient (screen positive for non-prescribed or illicit substances, or absence of prescribed substance). A positive urine drug screen may not necessarily result in dismissal of the patient, but it must be addressed. Actions could include referral for substance abuse counseling or treatment and refusal to prescribe further controlled substances.

ABERRANT BEHAVIOR

Aberrant behavior that may suggest medication misuse includes use of pain medications other than for pain treatment, impaired control (of self or of medication use), compulsive use of medication, continued use of medication despite harm (or lack of benefit), and craving or escalation of medication use.26 Other aberrant behaviors include selling or altering prescriptions, stealing or diverting medications, calls for early refills, losing prescriptions, drug-seeking behavior (e.g., doctor shopping), or reluctance to try nonpharmacologic interventions.26

PSYCHIATRIC ISSUES

Psychiatric problems commonly occur with chronic nonmalignant pain. In one study, 77 percent of those with chronic nonmalignant pain secondary to low back pain have a lifetime psychiatric diagnosis compared with 46 percent of the general U.S. population.33,34 Fifty-nine percent had a current and active psychiatric diagnosis compared with 26 percent of the general U.S. population.33,35 Common psychiatric disorders in those with chronic nonmalignant pain include anxiety; mood, personality, and somatoform disorders; and substance abuse.36

MEDICATION ADVERSE EFFECTS

Finally, medication adverse effects, especially of opioids, need to be addressed and anticipated. The most common adverse effects are somnolence, nausea, sedation (tolerance or resolution usually develops within 10 days), and constipation (no tolerance or resolution develops).37 Those on long-acting opioids should be started on long-term preventive therapy with a combination stimulant/softener laxative and considered for short-term (10 days) therapy with antinausea medication.37 The main etiology for constipation in patients taking opioids is slowing of stool transit time; therefore, avoidance of stool bulking agents is prudent because they can worsen constipation.31

Referral

When pain problems remain intractable and unremitting, referral to a pain management specialist may be helpful.26,31 Consultation can help provide other approaches to assessment or management of complex pain problems or determine interventional procedures to relieve pain. Psychosocial indications for a pain consultation can include a history of substance abuse, as well as interpersonal dynamics that seem to complicate the treatment of pain.33,36

The Authors

ROBERT P. JACKMAN, MD, is an assistant professor of family medicine at the Cascades East Family Medicine Residency Program, Oregon Health and Science University in Klamath Falls. He received his medical degree from the George Washington University School of Medicine and Health Sciences in Washington, DC, and completed a family medicine residency at the Cascades East Family Medicine Residency Program.

JANEY M. PURVIS, MD, is an adjunct clinical assistant family medicine professor at the Cascades East Family Medicine Residency Program, Oregon Health and Science University. She received her medical degree from McMaster University in Ontario, Canada, and completed a family medicine residency at the University of Alberta, Canada.

BARBARA S. MALLETT, MD, is an interventional pain management consultant at Spinal Diagnostics in Tualatin, Ore. She received her medical degree from the University of Kansas School of Medicine in Kansas City, Kan., and completed an anesthesia residency and a pain management fellowship at Dartmouth Medical School in Hanover, N.H. Dr. Mallett is a board-certified anesthesiologist with further board certification in pain management and hospice and palliative care.

Address correspondence to Robert P. Jackman, MD, Oregon Health and Science University, Cascades East Family Medicine Residency Program, 2801 Daggett Ave., Klamath Falls, OR 97601 (e-mail: Rjackman@skylakes.org). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

The authors acknowledge the contribution of Celia Freeman in the preparation of Figure 1 and Online Figure A; and acknowledge Lisa Poppe, Amber McKeen, Karen Langley, John Shaw, and Angela Ronnander in the preparation of the patient information handout. This work was supported in part by the Title VII Health Resources and Service Administration grant for curriculum development in primary care.

REFERENCES

1. Argoff C. Tailoring chronic pain treatment to the patient: long-acting, short-acting and rapid-onset opioids. Medscape Neurology & Neurosurgery. March 26, 2007. http://www.medscape.com/viewarticle/554015 [login required]. Accessed May 15, 2008.

2. Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. May 2004. http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf. Accessed May 22, 2008.

3. Carter C, Goldfarb NI, Hartmann CW, Roumm AR, Vallow SM, Durkin M. Chronic pain management in managed care organizations: a national survey of medical directors. Pharmacol Ther. 2003;28(3):179–215.

4. Pomm HA, Tenzer P. Perspectives on chronic pain. Abstract 277. Program and abstracts of the American Academy of Family Physicians Annual Scientific Assembly; September 28–October 2, 2005; San Francisco, Calif.

5. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372.

6. Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain. 1993;55(2):195–203.

7. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442.

8. Zwakhalen SM, van Dongen KA, Hamers JP, Abu-Saad HH. Pain assessment in intellectually disabled people: non-verbal indicators. J Adv Nurs. 2004;45(3):236–245.

9. Institute for Clinical Systems Improvement. Assessment and Management of Chronic Pain. 2nd ed.; March 2007. http://www.icsi.org/pain__chronic__assessment_and_management_of_14399/pain__chronic__assessment_and_management_of__guideline_.html. Accessed May 22, 2008.

10. Gallagher RM. Management of neuropathic pain: translating mechanistic advances and evidence-based research into clinical practice. Clin J Pain. 2006;22(1 suppl):S2–S8.

11. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1):1–39.

12. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006;25(suppl 1):S22–S29.

13. Koes BW, van Tulder MW, Ostelo R, Kim Burton A, Waddell G. Clinical guidelines for the management of low back pain in primary care: an international comparison. Spine. 2001;26(22):2504–2513.

14. Brookoff D. Chronic pain: 1. A new disease? Hosp Pract (Minneap). 2000;35(7):45–52,59.

15. Stanos S. Appropriate use of opioid analgesics in chronic pain. J Fam Pract. 2007;56(2):23–32.

16. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2008;(2):CD006145.

17. Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst Rev. 2004;(3):CD001878.

18. Eccleston C, Yorke L, Morley S, Williams AC, Mastroyannopoulou K. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2003;(1):CD003968.

19. Cepeda MS, Carr DB, Lau J, Alvarez H. Music for pain relief. Cochrane Database Syst Rev. 2006;(1):CD004843.

20. Eisenberg E, McNicol ED, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006;(3):CD006146.

21. Ballantyne JC. Opioids for chronic nonterminal pain. South Med J. 2006;99(11):1245–1255.

22. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;(1):CD003447.

23. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;(2):CD001133.

24. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(3):CD005454.

25. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007;(2):CD004846.

26. Portnoy RK, Payne R, Passik SD. Acute and chronic pain. In: Lowinson JH, ed. Substance Abuse: A Comprehensive Textbook. 4th ed., Baltimore, Md.: Williams & Wilkins; 2005:863–904.

27. Wisconsin Medical Society Task Force on Pain Management. Guidelines for the assessment and management of chronic pain. WMJ. 2004;103(3):13–42.

28. Fishbain DA. Polypharmacy treatment approaches to the psychiatric and somatic comorbidities found in patients with chronic pain. Am J Phys Med Rehabil. 2005;84(3 suppl):S56–S63.

29. Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract. 2001;14(3):211–218.

30. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage. 2004;28(2):176–188.

31. American Medical Association. Pain management: the online series. http://www.ama-cmeonline.com/pain_mgmt/. Accessed May 22, 2008.

32. Gourlay DL, Heit HA, Caplan YH. Urine drug testing in clinical practice: dispelling the myths and designing strategies. 3rd ed. Monograph PharmaCom Group, Inc., 2006.

33. Gatchel RJ. Psychological disorders and chronic pain. In: Gatchel RJ, Turk DC, eds. Psychological Approaches to Pain Management: A Practitioner's Handbook. New York, NY: Guilford Press, 1996:33–52.

34. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in Arch Gen Psychiatry. 2005;62(7):768]. Arch Gen Psychiatry. 2005;62(6):593–602.

35. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in Arch Gen Psychiatry. 2005;62(7):709.]. Arch Gen Psychiatry. 2005;62(6):617–627.

36. Gureje O. Psychiatric aspects of pain. Curr Opin Psychiatry. 2007;20(1):42–46.

37. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589–1594.


Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article